Biotech Accounting Red Flags: 5 in the Footnotes

You’re reading a biotech earnings press release. Non-GAAP loss per share narrowed to $0.48. Cash runway extends into 2028. The stock is up 8% in pre-market. Here’s what the press release didn’t tell you, and what the 10-Q footnotes actually say.

Wall Street analysts read the press release. You’re going to read the footnotes. That’s where the money is, because a biotech with no revenue can’t play the classic revenue-recognition games. It plays different ones. Here are the five red flags, where to find them, and the math that exposes them.

Red Flag 1: R&D capitalization

GAAP says research and development gets expensed as it’s incurred (ASC 730). Spend $50 million on a trial, book a $50 million expense that quarter. No exceptions.

But acquired in-process research and development (IPR&D) is different. When a company buys another company’s unapproved drug, that drug’s value lands on the balance sheet as an indefinite-lived intangible asset (ASC 805). It sits there with no amortization until the drug either works, which reclassifies it as a definite-lived asset, or fails, which triggers one brutal impairment charge all at once.

The red flag is a balance sheet loaded with IPR&D. AbbVie paid $5.8 billion for Stemcentrx in 2016 and took a roughly $4 billion write-down when the lead drug Rova-T failed its small cell lung cancer trials in 2019. The entire value of the acquisition was IPR&D, so the failure went straight to the income statement. Watch the line item “acquired in-process research and development” under intangible assets. If it’s large relative to the company’s market cap, one failed trial can vaporize it overnight.

Red Flag 2: The cash runway fudge

Every press release says “cash runway into 2028.” The footnotes tell a different story. Runway estimates assume zero new hires, zero trial acceleration, and zero milestone payments.

Here’s the simple math the company hopes you won’t do. If cash is $400 million and last quarter’s burn was $80 million, the company says “five quarters of runway, mid-2027.” But enrolling a Phase 3 trial and hiring a commercial team means burn will rise, not stay flat. Run the adjusted number: cash divided by quarterly burn times 1.2. That’s $400M divided by $96M, or 4.2 quarters, not five. The difference is the company running dry one quarter before you expected a raise.

Get the real burn rate from the statement of cash flows in the 10-Q, never from the press release. As a rule of thumb, under 12 months of runway means dilution is coming within 90 days; 12-18 months means it’s likely but management is waiting for a catalyst; over 24 months means you have a buffer.

Red Flag 3: The dilution time bomb

Warrants, convertible notes, and pre-funded warrants are dilution that hasn’t hit the share count yet. The real denominator is the fully diluted share count.

Find it in the 10-Q under “potentially dilutive securities” and the treasury stock method table. A company with 50 million shares outstanding and 30 million in-the-money warrants has 80 million fully diluted, a 60% overhang the market isn’t pricing. When those warrants convert, every dollar of a future buyout gets split across 60% more holders. The dilution math is unforgiving: a $150 million raise at a $500 million market cap is roughly 25-30% effective dilution once you add the offering discount and the announcement-day drop. For the full mechanics of how dilution plays out, see the biotech dilution survival guide.

Red Flag 4: Non-GAAP earnings that exclude everything

Biotech’s favorite trick is non-GAAP EPS that excludes stock-based compensation (SBC). For a pre-revenue company, SBC is often 20-40% of operating costs. It’s real compensation; it just doesn’t consume cash this quarter.

When the non-GAAP loss is $0.50 a share and the GAAP loss is $1.20, that $0.70 gap is real expense. The reconciliation is mandatory and sits right in the earnings release under “non-GAAP financial measures.” If the gap between GAAP and non-GAAP is widening quarter over quarter, the company is paying its people more in paper than it’s willing to count as a cost. For the five numbers that actually matter in a biotech earnings report, see the biotech earnings guide.

Red Flag 5: Related-party transactions

The CEO’s brother runs a contract research organization (CRO) the company pays $5 million a quarter. The CFO’s former firm is lead underwriter on every offering. These land in the 10-K footnotes under Item 13, related-party transactions, the most unread section in biotech financials.

The signal isn’t the dollar amount. It’s the governance. When insiders route company cash to entities they control, your interests and theirs have already diverged. Pull the 10-K on SEC EDGAR and search “related party.” If that section is more than a paragraph, find out why before you own the stock.

The 10-minute red flag screen

Before you own any biotech, run these five checks:

1. Cash divided by quarterly burn, adjusted up 20%.
2. Fully diluted share count versus shares outstanding.
3. Last three quarters of the GAAP to non-GAAP reconciliation.
4. Search the 10-K for “related party.”
5. Read the going-concern note in the 10-Q.

One note on the going-concern language. If the auditors say there’s “substantial doubt” about the company’s ability to continue as a going concern, the runway math no longer matters. That note appears when the company has enough cash for less than about a year, and it’s usually the last warning before a dilutive raise or a fire sale.

Common mistakes

Buying the pre-market pop on a “narrowed loss.” The narrowing usually comes from the non-GAAP math in Red Flag 4, not from the business improving. The GAAP number barely moved.

Trusting the stated runway. The company told you “into 2028” while the adjusted math says early 2027. You learn about the dilutive offering the same way everyone else does: the stock gaps down 20% on the announcement.

Ignoring the fully diluted count. You model 50 million shares, the warrants convert, and the buyout price you were underwriting gets split 80 million ways.

Final checklist

• Cash divided by (burn times 1.2) gives at least six quarters of real runway.
• Fully diluted shares versus outstanding: overhang under 20%.
• GAAP versus non-GAAP gap: stable, not widening.
• Related-party section: one paragraph or less.
• Going-concern note: clean.

The press release is written to make you feel good. The footnotes are written because the SEC requires them. One of those documents tells you the truth.